|
| 37001964 | Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. | | 2023 |
| 37640457 | Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial. | | 2023 |
| 37147136 | Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection. | | 2023 |
| 36895286 | Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. | | 2023 |
| 37075126 | An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. | | 2023 |
| 36582240 | Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings. | Front Immunol | 2022 |
| 36357712 | Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. | Nat Microbiol | 2022 |
| 36094485 | Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children. | J Acquir Immune Defic Syndr | 2022 |
| 36093348 | Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination. | | 2022 |
| 35759653 | Early human B cell signatures of the primary antibody response to mRNA vaccination. | Proceedings of the National Academy of Sciences of the United States of America | 2022 |
| 35441174 | Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial. | medRxiv | 2022 |
| 35378757 | Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. | bioRxiv | 2022 |
| 36128909 | Clinical outcomes and immune responses to SARS-CoV-2 vaccination in severe aplastic anaemia. | Br J Haematol | 2022 |
| 36257313 | Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. | Cell | 2022 |
| 35921449 | Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria. | New England Journal of Medicine | 2022 |
| 35783486 | Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. | eClinicalMedicine | 2022 |
| 36317783 | Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali. | New England Journal of Medicine | 2022 |
| 36517467 | Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. | Nat Commun | 2022 |
| 34426813 | Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates. | bioRxiv | 2021 |
| 34020817 | A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation. | Vaccine | 2021 |
| 33582148 | A sensitive method to quantify HIV-1 antibodies in mucosal samples. | Journal of Immunological Methods | 2021 |
| 34166231 | Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. | J Clin Invest | 2021 |
| 34268520 | Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccine. | medRxiv | 2021 |
| 34210892 | Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. | Science | 2021 |
| 33720905 | A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2. | JCI insight | 2021 |
| 33826898 | Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. | Cell Reports | 2021 |
| 33442707 | Fever, Diarrhea, and Severe Disease Correlate with High Persistent Antibody Levels against SARS-CoV-2. | medRxiv | 2021 |
| 33655252 | Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants. | bioRxiv | 2021 |
| 33755731 | Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses. | J Infect Dis | 2021 |
| 33495459 | Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. | npj Vaccines | 2021 |
| 34398806 | Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2. | Immunohorizons | 2021 |
| 34672695 | Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. | Science | 2021 |
| 34379916 | A Monoclonal Antibody for Malaria Prevention. | New England Journal of Medicine | 2021 |
| 33182279 | Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies. | Vaccines (Basel) | 2020 |
| 32295908 | Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. | Journal of Virology | 2020 |
| 31004012 | Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine. | Sci Immunol | 2019 |
| 29237774 | Quantitative Multiplexed Imaging Analysis Reveals a Strong Association between Immunogen-Specific B Cell Responses and Tonsillar Germinal Center Immune Dynamics in Children after Influenza Vaccination. | Journal of Immunology | 2018 |
| 30517201 | Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. | PLoS Pathog | 2018 |
| 29364886 | Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. | PLoS Medicine | 2018 |
| 29212041 | Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. | Cell Reports | 2017 |
| 28825711 | Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. | Nature Chemical Biology | 2017 |
| 28445724 | Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. | Cell Rep | 2017 |
| 28783708 | Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. | Science immunology | 2017 |
| 26689967 | Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. | Nat Struct Mol Biol | 2016 |
| 27453470 | Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. | Cell | 2016 |
| 26279189 | Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. | Cell | 2015 |
| 25740988 | Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. | Journal of Virology | 2015 |
| 26719262 | Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. | Journal of Virology | 2015 |
| 26098315 | Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. | Nat Struct Mol Biol | 2015 |
| 26078272 | H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. | J Immunol | 2015 |